J. Naderer J. Naderer Asuphon

140 SCIENTIFIC SESSIONS September 9-12 | A-1264 PK and Bactericidal Activity in Sputum and Blood of PNU- 100480 Sutezolid, U-480 and its Major Metabolite PNU- 101603, U-603 in Patients with Pulmonary TB

R. S. Wallis

1 , S. O. Friedrich 2 , A. H. Diacon 2 , R. Dawson 3 , A. Venter 2 , D. Paige 1 , T. Zhu 1 , A. Silvia 1 , J. Gobey 1 , C. Ellery 1 , Y. Zhang 1 ; 1 Pfizer, Gro- ton, CT, 2 Stellenbosch Univ., Stellenbosch, South Africa, 3 Univ. Cape Town, Cape Town, South Africa. A-1265 Pharmacodynamics of PNU-100480 U, Sutezolid, a New Oxazolidinone, in Combination with its Active Metabolite in the Killing of Mycobacterium tuberculosis Mtb in an In Vitro Hollow Fiber Infection Model HFIM

A. Louie, D. Brown, K. Files, M. Swift, S. Fikes, G. Drusano; Univ. of Florida, Orlando, FL.

A-1266 A New Mathematical Model for Anti-Infective Pharma- cokineticsPharmacodynamics PKPD which Accommodates Random Mutations

A. Forrest

1,2 , O. O. Okusanya 1,2 , J. B. Bulitta 3 ; 1 SUNY Sch. of Pharmacy, Buffalo, NY, 2 ICPD, Latham, NY, 3 Monash Univ., Melbourne, Australia. A-1267 Tissue Distribution and Macrophages Uptake for Novel Spectinamide Drug Candidates against Tuberculosis

A. Trivedi

1 , D. Madhura 1 , J. Liu 2 , K. Kromke 1 , C. Rathi 1 , V. Loveless 1 , R. E. Lee 2 , B. Meibohm 1 ; 1 Univ. of Tennessee Hlth. Sci. Ctr., Memphis, TN, 2 St. Jude Children’s Res. Hosp., Memphis, TN. A-1268 Increasing Rifampicin Dosage in the Treatment of Murine Tuberculosis Allows Reduction of Therapy Duration

G. J. de Knegt

1 , R. E. Aarnoutse 2 , M. T. Ten Kate 1 , M. J. Boeree 2 , D. van Soolingen 3 , I. A. Bakker-Woudenberg 1 , J. E. M. de Steenwinkel 1 ; 1 Erasmus Univ. Med. Ctr., Rotterdam, Netherlands, 2 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 3 Natl. Inst. of Publ. Hlth. and the Environ- ment, Bilthoven, Netherlands. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 162A Poster Session Clinical Pharmacology of Novel Anti-Infective Agents Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-1269 Population Pharmacokinetic PPK and Pharmacokinetic Pharmacodynamic PKPD Target Attainment TA Analyses for Solithromycin SOL, CEM-101 to Support Intravenous IV Dose Selection in Patients with Community-Acquired Bacterial Pneumonia CABP O. O. Okusanya 1 , S. M. Bhavnani 1 , A. Forrest 1 , C. C. Bulik 1 , D. Oldach 2 , P. Fernandes 2 , P. G. Ambrose 1 ; 1 ICPD, Latham, NY, 2 Cempra Pharmaceuti- cals, Chapel Hill, NC. A-1270 Evaluation of the PharmacokineticsPharmacodynamics PKPD of GSK2251052 GSK052 against Gram-Negative Bacilli GNB in a Murine-Thigh Infection Model C. C. Bulik 1 , O. O. Okusanya 1 , S. M. Bhavnani 1 , A. Lepak 2 , A. Forrest 1 , P. G. Ambrose 1 , J. L. Hoover 3 , D. R. Andes 2 ; 1 ICPD, Latham, NY, 2 Univ. of Wisconsin, Madison, WI, 3 GlaxoSmithKline, Collegeville, PA. A-1271 Evaluation of the PharmacokineticsPharmacodynamics PKPD of GSK2251052 GSK052 against Gram-Negative Bacilli GNB Using Data from a Neutropenic Murine- Pneumonia Infection Model

D. R. Andes

1 , O. O. Okusanya 2 , C. C. Bulik 2 , A. Lepak 1 , S. M. Bhavnani 2 , A. Forrest 2 , J. L. Hoover 3 , P. G. Ambrose 2 ; 1 Univ. of Wisconsin, Madison, WI, 2 ICPD, Latham, NY, 3 GlaxoSmithKline, Collegeville, PA. A-1272 Pharmacokinetics and Safety of Oral GSK2251052, a Novel, Boron-Containing Antimicrobial, in Healthy Subjects

E. Dumont

1 , D. Tenero 1 , M. Barton 1 , J. Bianco 2 , S. Shakib 3 , M. Kurtinecz 1 , P. Patel 4 , J. Tomayko 1 ; 1 GlaxoSmithKline, Philadelphia, PA, 2 GlaxoSmith- Kline, Abbotsford, Australia, 3 CMAX, Adelaide, Australia, 4 GlaxoSmith- Kline, RTP, NC. A-1273 Cadazolid, a Novel Antibiotic with Potent Activity against Clostridium difficile: Safety, Tolerability, and Pharmacokinetics in Healthy Subjects following Single and Multiple Oral Doses

D. Baldoni

1 , M. Gutierrez 1 , J. Dingemanse 1 , W. Timmer 2 ; 1 Actelion Phar- maceuticals Ltd., Allschwil, Switzerland, 2 Clinical Res. Services Mannheim GmbH, Mannheim, Germany. A-1274 Mutant Prevention Concentration of Fidaxomicin for Clostridium difficile

J. Seddon, F. Babakhani, P. Sears; Optimer Pharmaceuticals, San Diego, CA. A-1275

PharmacokineticsPharmacodynamics PKPD of Peptide Deformylase PDF Inhibitor GSK1322322 GSK322 against Streptococcus pneumoniae in a Mouse Pneumonia Model J. L. Hoover, R. J. Straub, S. J. Novick, O. J. Naderer, S. Rittenhouse; Glaxo- SmithKline, Collegeville, PA. A-1276 Intravenous IV First Time in Human Safety and Phar- macokinetics of GSK1322322 GSK322, a Peptide Deformylase Inhibitor Antibacterial

O. J. Naderer

1 , L. S. Jones 1 , J. Z. Zhu 2 , M. Kurtinecz 3 , E. F. Dumont 3 ; 1 GlaxoSmithKline, Research Triangle Park, NC, 2 GlaxoSmithKline, Upper Merion, PA, 3 GlaxoSmithKline, Upper Providence, PA. A-1277 Penetration of GSK1322322 GSK322 into Epithelial Lining Fluid ELF and Alveolar Macrophages AM as Determined by Bronchoalveolar Lavage BAL

O. J. Naderer

1 , K. A. Rodvold 2 , L. S. Jones 1 , J. Z. Zhu 3 , E. F. Dumont 4 ; 1 GlaxoSmithKline, Research Triangle Park, NC, 2 Univ. of Illinois at Chicago, IL, 3 GlaxoSmithKline, Upper Merion, PA, 4 GlaxoSmithKline, Upper Provi- dence, PA. A-1278 The Monoclonal Antibody Panobacumab KBPA101 Improves Pseudomonas aeruginosa PA Opsonophagocytosis by THP-1 Monocytes H. Jacqmin, J. Buyck, P. M. Tulkens, F. Van Bambeke; Univ. Catholique de Louvain, Bruxelles, Belgium. A-1279 Optimizing Fosfomycin Dosing for Treatment of Pseudo- monas aeruginosa Infections in Critically-Ill Patients Based on PharmacokineticsPharmacodynamics PKPD Target

O. Asuphon

1 , P. Montakantikul 2 , J. Haungsaitong 2 , P. Sonthisombat 1 , P. Kiratisin 3 ; 1 Naresaun Univ., Pitsanulok, Thailand, 2 Mahidol Univ., Bangkok, Thailand, 3 Siriraj Hosp., Mahidol Univ., Bangkok, Thailand. 141 TUESDAY SCIENTIFIC SESSIONS Final Program A-1280 Tigecycline and Enterobacter Invasive Infections: PKPD Parameters Using Monte Carlo Simulation J. Lepe 1 , C. Martín-Gandul 1 , J. Rodríguez-Martínez 2 , O. Gasch 3 , C. Ruiz de Alegría 4 , R. Lara 5 , C. Fernández-Mazarrasa 4 , F. Tubau 3 , F. Rodríguez-López 5 , L. Martínez-Martínez 4 , M. Jiménez-Mejías 1 ; 1 Univ. Hosp. Virgen del Rocío, Sevilla, Spain, 2 Univ. Hosp. Virgen Macarena, Sevilla, Spain, 3 Univ. Hosp. Bellvitge, Barcelona, Spain, 4 Univ. Hosp. Marqués de Valdecillas, Santander, Spain, 5 Univ. Hosp. Reina Sofía, Córdoba, Spain. A-1281 Pharmacokinetics of [14c]-Labeled Omadacycline PTK 0796 in Healthy Male Subjects H. Sun 1 , L. Ting 1 , J. Flarakos 1 , K. Dole 1 , J. Praestgaard 1 , S. J. Kovacs 1 , D. S. Stein 1 , G. Sunkara 1 , S. K. Tanaka 2 ; 1 Novartis, East Hanover, NJ, 2 Paratek Pharmaceuticals, Boston, MA. A-1282 Pharmacokinetics of Omadacycline PTK 0796 in Subjects with Hepatic Impairment L. Ting 1 , S. J. Kovacs 1 , J. Praestgaard 1 , R. Maietta 2 , D. S. Stein 1 , G. Sunkara 1 ,

M. P. Draper